Clinical Trial Update: Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating intermittent chemotherapy with or without GM-CSF in metastatic hormone-refractory prostate cancer; results posted after completi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-11-20